Mode
Text Size
Log in / Sign up

Hypertrophic obstructive cardiomyopathy

Part of Cardiomyopathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypertrophic obstructive cardiomyopathy

5 trials tracked for Hypertrophic obstructive cardiomyopathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 105 citations.

5Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1 Other / NA 1
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM Completed · 105 cited
  2. Phase 3 Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Completed · 96 cited
  3. Phase 3 A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Completed
  4. Phase 2 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction Completed
  5. N/A Advancing Understanding of Transportation Options Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypertrophic obstructive cardiomyopathy: what the trials found

Mavacamten has demonstrated efficacy in reducing LVOT peak gradients in patients with hypertrophic obstructive cardiomyopathy. At week 30, a significant proportion of participants achieved a Valsalva LVOT peak gradient of < 30 mmHg 1 and < 50 mmHg 1.

Clinical improvements associated with mavacamten include a measurable reduction in the severity of HCM symptoms as measured by the HCMSQ score 2 and an improvement in health-related quality of life (KCCQ score) at week 30 2. Additionally, approximately 63.2% of patients treated with mavacamten showed at least one class improvement in their New York Heart Association (NYHA) functional class by week 30 3.

Recent results — preliminary, needs further review

  • MYK-461 showed a reduction in dyspnea symptom scores from baseline to week 12, with some participants achieving a post-exercise peak LVOT gradient of < 30 mmHg 4.
  • A driving decision aid was evaluated for older adults, showing improvements in values clarity and safety knowledge scores 5.

For the clinician treating this condition

  • Mavacamten is associated with significant reductions in LVOT peak gradients at week 30 1.
  • Mavacamten treatment correlates with improved patient-reported quality of life (KCCQ) and reduced symptom severity (HCMSQ) 2.
  • A majority of patients treated with mavacamten experienced an improvement in NYHA functional class by week 30 3.

AI synthesis of 5 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cardiomyopathy

Related studies from across the Cardiomyopathy family.

Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome
Cardiology Meta-analysis
Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome Heart conditions like Brugada syndrome increase risk of rapid heartbeats
This systematic review of 30 studies indicates that supraventricular tachyarrhythmias (SVT) are more frequent in patients with Arrhythmogeni…
Patients with certain heart conditions face a higher risk of fast heartbeats, which can lead to complications like heart failure or unnecess…
Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathy
Physical Medicine & Rehab Meta-analysis
Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathy Exercise improves heart health and fitness for HCM patients
This meta-analysis of 9,702 patients with hypertrophic cardiomyopathy (HCM) found that exercise is associated with increased peak oxygen con…
New research shows that structured exercise can improve heart fitness, body weight, and quality of life for people with hypertrophic cardiom…
Global Longitudinal Strain as a Potential Predictor of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Radiology & Imaging Meta-analysis
Global Longitudinal Strain as a Potential Predictor of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Heart imaging helps identify high risk in cardiomyopathy patients
Meta-analysis suggests reduced global longitudinal strain identifies high-risk patients with hypertrophic cardiomyopathy prone to fatal arrh…
A new way to measure heart muscle movement may help doctors identify which patients with a specific heart condition are at higher risk for s…
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases
Oncology Sys. Review
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases How blood vessel cells drive heart disease and high blood pressure
This narrative review synthesizes mechanisms of VSMC-immune interactions in atherosclerosis, hypertension, aortic aneurysms, and arteritis. …
A new review reveals how blood vessel cells change in heart disease, high blood pressure, and more.
Review of Diabetic Cardiomyopathy without reported trial data or specific outcomes
Cardiology Sys. Review
Review of Diabetic Cardiomyopathy without reported trial data or specific outcomes Review of Diabetic Cardiomyopathy offers new understanding of this heart condition
This narrative review addresses Diabetic cardiomyopathy but reports no specific population, sample size, or intervention details. The author…
This review looks at diabetic cardiomyopathy to help doctors understand this specific heart problem better for patients with diabetes.
Mini review examines sudden cardiac death risks in marathon runners across different age groups
Cardiology Sys. Review
Mini review examines sudden cardiac death risks in marathon runners across different age groups Marathon running links to higher heart risk in older men and full-distance participants
This mini review synthesizes evidence on sudden cardiac death (SCD) and coronary artery disease in marathon runners. The authors note that r…
A review of marathon runners shows heart risks vary by age, sex, and race distance, with most events happening near the finish.
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications
Diabetes & Endocrinology Sys. Review
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications New research shows mushroom compounds may help control blood sugar and fix organ damage
This narrative review examines the theoretical potential of Ganoderma lucidum polysaccharides (GLPs) for diabetes and associated conditions.
A common mushroom extract could help lower blood sugar and heal organ damage for millions of people with diabetes
Deep learning model screens for transthyretin amyloid cardiomyopathy using ECG images
Cardiology Cohort
Deep learning model screens for transthyretin amyloid cardiomyopathy using ECG images AI spots hidden heart disease from routine ECGs
This observational study developed a deep learning model to identify transthyretin amyloid cardiomyopathy from ECG images.
A new AI tool finds signs of a dangerous heart disease in routine ECGs years before symptoms worsen, offering hope for earlier treatment in …
Acoramidis associated with lower diuretic intensification in transthyretin amyloid cardiomyopathy
Cardiology Cohort
Acoramidis associated with lower diuretic intensification in transthyretin amyloid cardiomyopathy New Heart Drug Shows Lower Risk of Hospitalization vs Older Option
In this retrospective cohort study using US claims data, acoramidis was associated with a lower risk of diuretic intensification and a compo…
A new heart drug cut diuretic needs and hospitalizations more than the older option in early real-world use.
PSI-QPI metrics improved prediction of TTN-TV disease penetrance and expressivity in cardiomyopathy patients
Cardiology Cohort
PSI-QPI metrics improved prediction of TTN-TV disease penetrance and expressivity in cardiomyopathy patients New Tool Predicts Heart Failure Risk in Genetic Heart Disease
This cohort study evaluated PSI-DCM-LR-15, QPI, and PSI-QPI metrics in patients with cardiomyopathy due to TTN-TV and cardiac tissue from or…
A new combination of tests can more accurately predict which patients with genetic heart muscle disease will develop serious heart failure.
Review of Visual Standardized Quantification for LGE in Cardiomyopathy
Cardiology
Review of Visual Standardized Quantification for LGE in Cardiomyopathy A new tool improves accuracy and speed for spotting heart risks in patients with cardiomyopathy
This narrative review synthesizes evidence on Visual Standardized Quantification of LGE (VISTAQ) versus conventional techniques.
A new imaging method showed better accuracy and faster analysis times for predicting heart events in patients with specific heart diseases.
Review synthesizes genetic insights and CMR imaging traits as potential therapeutic targets for cardiomyopathies
Cardiology
Review synthesizes genetic insights and CMR imaging traits as potential therapeutic targets for cardiomyopathies New Clues to Treating Heart Muscle Diseases Found in Your Genes
This Mendelian randomization and imaging mediation analysis review identifies potential therapeutic targets for hypertrophic and dilated car…
This study connects your genes to specific heart changes, opening the door to more personalized treatments for heart muscle disease.